WO2005030039A2 - Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin k epoxide reductase gene and warfarin dosage - Google Patents
Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin k epoxide reductase gene and warfarin dosage Download PDFInfo
- Publication number
- WO2005030039A2 WO2005030039A2 PCT/US2004/031481 US2004031481W WO2005030039A2 WO 2005030039 A2 WO2005030039 A2 WO 2005030039A2 US 2004031481 W US2004031481 W US 2004031481W WO 2005030039 A2 WO2005030039 A2 WO 2005030039A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- warfarin
- subject
- vkor
- single nucleotide
- nucleotide polymorphism
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/573,131 US7687233B2 (en) | 2003-09-23 | 2004-09-23 | Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage |
AU2004275828A AU2004275828B2 (en) | 2003-09-23 | 2004-09-23 | Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage |
JP2006528251A JP2007506433A (en) | 2003-09-23 | 2004-09-23 | Methods and compositions for correlating single nucleotide polymorphisms in the vitamin K epoxide reductase gene with warfarin dose |
CA2539434A CA2539434C (en) | 2003-09-23 | 2004-09-23 | Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin k epoxide reductase gene and warfarin dosage |
EP04789039.7A EP1670947B1 (en) | 2003-09-23 | 2004-09-23 | Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin k epoxide reductase gene and warfarin dosage |
US11/516,229 US7524665B2 (en) | 2003-09-23 | 2006-09-06 | Methods and compositions for vitamin K epoxide reductase |
HK06114003.0A HK1093223A1 (en) | 2003-09-23 | 2006-12-20 | Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin epoxide reductase gene and warfarin dosage |
US11/699,930 US7482141B2 (en) | 2003-09-23 | 2007-01-30 | Methods and compositions for vitamin K epoxide reductase |
US11/787,072 US7645602B2 (en) | 2003-09-23 | 2007-04-13 | Methods and compositions for producing vitamin K dependent proteins |
US11/924,707 US8097410B2 (en) | 2003-09-23 | 2007-10-26 | Methods and compositions for vitamin K epoxide reductase |
US12/361,053 US7858318B2 (en) | 2003-09-23 | 2009-01-28 | Methods and compositions for vitamin K epoxide reductase |
AU2010203318A AU2010203318B2 (en) | 2003-09-23 | 2010-07-26 | Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage |
US12/971,574 US8426128B2 (en) | 2003-09-23 | 2010-12-17 | Methods and compositions for vitamin K epoxide reductase |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50552703P | 2003-09-23 | 2003-09-23 | |
US60/505,527 | 2003-09-23 |
Related Child Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10573131 A-371-Of-International | 2004-09-23 | ||
US11/516,229 Continuation US7524665B2 (en) | 2003-09-23 | 2006-09-06 | Methods and compositions for vitamin K epoxide reductase |
US11/699,930 Continuation US7482141B2 (en) | 2003-09-23 | 2007-01-30 | Methods and compositions for vitamin K epoxide reductase |
US11/787,072 Continuation-In-Part US7645602B2 (en) | 2003-09-23 | 2007-04-13 | Methods and compositions for producing vitamin K dependent proteins |
US11/924,707 Continuation US8097410B2 (en) | 2003-09-23 | 2007-10-26 | Methods and compositions for vitamin K epoxide reductase |
US12/361,053 Continuation US7858318B2 (en) | 2003-09-23 | 2009-01-28 | Methods and compositions for vitamin K epoxide reductase |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005030039A2 true WO2005030039A2 (en) | 2005-04-07 |
WO2005030039A3 WO2005030039A3 (en) | 2005-07-21 |
Family
ID=34393028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/031481 WO2005030039A2 (en) | 2003-09-23 | 2004-09-23 | Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin k epoxide reductase gene and warfarin dosage |
Country Status (13)
Country | Link |
---|---|
US (6) | US7687233B2 (en) |
EP (4) | EP2336360A1 (en) |
JP (4) | JP2007506433A (en) |
AT (1) | ATE455174T1 (en) |
AU (2) | AU2004275828B2 (en) |
CA (1) | CA2539434C (en) |
DE (1) | DE602004025157D1 (en) |
DK (2) | DK2380985T3 (en) |
ES (2) | ES2453895T3 (en) |
HK (1) | HK1093223A1 (en) |
PL (1) | PL1842920T5 (en) |
PT (1) | PT2380985E (en) |
WO (1) | WO2005030039A2 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006044686A3 (en) * | 2004-10-18 | 2006-08-03 | Univ Washington | Methods and compositions for predicting drug responses |
JP2007512002A (en) * | 2003-10-14 | 2007-05-17 | バクスター・インターナショナル・インコーポレイテッド | Therapeutic targets for vitamin K epoxy recycling polypeptide VKORC1, coumarin and its derivatives |
WO2007075976A2 (en) * | 2005-12-21 | 2007-07-05 | Inspiration Biopharmaceuticals, Inc. | Method of producing biologically active vitamin k dependent proteins by recombinant methods |
EP1861499A1 (en) * | 2005-03-15 | 2007-12-05 | The University of North Carolina at Chapel Hill | Methods and compositions for producing active vitamin k-dependent proteins |
KR20080002949A (en) * | 2005-04-13 | 2008-01-04 | 아스트라제네카 아베 | A host cell comprising a vector for production of proteins requiring gamma-carboxylation |
JP2008531026A (en) * | 2005-02-28 | 2008-08-14 | バクスター・インターナショナル・インコーポレイテッド | Recombinant co-expression of vitamin K epoxide reductase subunit 1 to improve vitamin K-dependent protein expression |
US7445896B2 (en) * | 2004-10-18 | 2008-11-04 | University Of Washington | Methods and compositions for detecting VKORC1 single nucleotide polymorphisms |
US7482141B2 (en) | 2003-09-23 | 2009-01-27 | University Of North Carolina At Chapel Hill | Methods and compositions for vitamin K epoxide reductase |
WO2009130602A2 (en) | 2008-04-24 | 2009-10-29 | Celtic Pharma Peg Ltd. | Factor ix conjugates with extended half-lives |
EP1831402B1 (en) * | 2004-12-21 | 2010-06-09 | Academia Sinica | Genetic variants of vkorc1 predicting warfarin sensitivity |
US7842477B2 (en) | 2003-10-14 | 2010-11-30 | Astrazeneca Ab | Methods for producing gamma-carboxylated proteins |
US8206967B2 (en) | 2007-07-06 | 2012-06-26 | Medimmune Limited | Method for production of recombinant human thrombin |
JP2012139232A (en) * | 2012-03-15 | 2012-07-26 | Univ Of North Carolina At Chapel Hill | Method and composition for producing active vitamin k-dependent protein |
JP2014221048A (en) * | 2014-06-16 | 2014-11-27 | ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Method and composition for producing active vitamin k-dependent protein |
US9212214B2 (en) | 2009-07-10 | 2015-12-15 | Csl Limited | Methods of increasing the expression yield of vitamin K-dependent proteins |
US9631002B2 (en) | 2010-12-21 | 2017-04-25 | The University Of North Carolina At Chapel Hill | Methods and compositions for producing active vitamin K-dependent proteins |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006012902A2 (en) * | 2004-08-02 | 2006-02-09 | Novozymes A/S | Creation of diversity in polypeptides |
US8500720B2 (en) * | 2005-05-09 | 2013-08-06 | Medtronic, Inc | Method and apparatus for treatment of cardiac disorders |
WO2007143617A1 (en) * | 2006-06-02 | 2007-12-13 | Academia Sinica | Warfarin dosage prediction |
WO2010045381A2 (en) * | 2008-10-15 | 2010-04-22 | President And Fellows Of Harvard College | Antimicrobial agents that target bacterial vkor |
BR102015012334A2 (en) | 2015-05-27 | 2016-11-29 | Fundação Hemoct De Ribeirão Preto Fundherp | production process of blood coagulation factor vii and blood coagulation factor vii |
CN110087530A (en) | 2016-12-07 | 2019-08-02 | 普罗根尼蒂公司 | Gastrointestinal tract detection method, device and system |
WO2018112264A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
EP3883635A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
EP3870261B1 (en) | 2019-12-13 | 2024-01-31 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DE3485810T2 (en) | 1983-05-27 | 1992-12-10 | Texas A & M Univ Sys | METHOD FOR PRODUCING A RECOMBINANT BACULOVIRUS EXPRESSION VECTOR. |
US4736866A (en) * | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
US4770999A (en) | 1985-04-22 | 1988-09-13 | Genetics Institute, Inc. | High yield production of active Factor IX |
DE3785186T2 (en) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | BINDING MOLECULE WITH SINGLE POLYPEPTIDE CHAIN. |
WO1988003926A1 (en) | 1986-11-17 | 1988-06-02 | New England Medical Center | Enhancing gamma-carboxylation of recombinant vitamin k-dependent proteins |
JPH03501921A (en) | 1987-05-18 | 1991-05-09 | インテグレイテッド・ジェネティクス・インク | Improved protein molecules and methods for their production and activation |
KR0184860B1 (en) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | Single domain ligands receptors comprising said ligands methods for their production and use of said ligands |
WO1991001372A1 (en) | 1989-07-17 | 1991-02-07 | New England Medical Center Hospitals, Inc. | VITAMIN K-DEPENDENT η-CARBOXYLASE |
EP0540650A1 (en) * | 1990-07-23 | 1993-05-12 | Zymogenetics, Inc. | Gamma-carboxylase and methods of use |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5169784A (en) | 1990-09-17 | 1992-12-08 | The Texas A & M University System | Baculovirus dual promoter expression vector |
JP4236698B2 (en) | 1990-11-26 | 2009-03-11 | ジェネティックス インスティチュート,リミテッド ライアビリティ カンパニー | Expression of PACE in host cells and uses thereof |
US5965789A (en) | 1991-01-11 | 1999-10-12 | American Red Cross | Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals |
US5268275A (en) | 1991-05-08 | 1993-12-07 | The University Of North Carolina At Chapel Hill | Vitamin K-dependent carboxylase |
DE69229477T2 (en) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Tech | Methods for the production of humanized antibodies |
US5698765A (en) * | 1991-12-02 | 1997-12-16 | The Ontario Cancer Institute | Mouse having a disrupted CD4 gene |
WO1993018144A1 (en) * | 1992-03-05 | 1993-09-16 | The Trustees Of Columbia University Of The City Of New York | Recombination activating gene deficient animal |
US5625122A (en) * | 1992-04-24 | 1997-04-29 | The Ontario Cancer Institute | Mouse having a disrupted lck gene |
JP3741447B2 (en) * | 1992-10-23 | 2006-02-01 | 中外製薬株式会社 | Mice deficient in endothelin-1 gene function |
US5605798A (en) * | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
US5547835A (en) * | 1993-01-07 | 1996-08-20 | Sequenom, Inc. | DNA sequencing by mass spectrometry |
AU2860295A (en) | 1994-06-16 | 1996-01-05 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Defects in drug metabolism |
ZA965853B (en) * | 1995-07-13 | 1998-01-12 | Du Pont Merck Pharma | Asymmetric synthesis of r and s warfarin and its analogs. |
DE19625049A1 (en) | 1996-06-22 | 1998-01-02 | Inst Pflanzengenetik & Kultur | Transgenic, non-human mammal that contains an additional DNA repair gene |
WO2002090526A2 (en) | 2001-03-21 | 2002-11-14 | Human Genome Sciences, Inc. | Human secreted proteins |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
WO1999003496A1 (en) | 1997-07-21 | 1999-01-28 | The University Of North Carolina At Chapel Hill | Factor ix antihemophilic factor with increased clotting activity |
WO1999033983A1 (en) | 1997-12-24 | 1999-07-08 | Immunex Corporation | V201 dna and polypeptides |
US5896337A (en) | 1998-02-23 | 1999-04-20 | Micron Technology, Inc. | Circuits and methods for multi-level data through a single input/ouput pin |
WO2000003015A2 (en) * | 1998-07-10 | 2000-01-20 | Incyte Pharmaceuticals, Inc. | Human transport protein homologs |
DE69911578D1 (en) * | 1998-11-18 | 2003-10-30 | Koninkl Philips Electronics Nv | LUMINOUS MATERIAL |
WO2000054787A1 (en) | 1999-03-16 | 2000-09-21 | The Children's Hospital Of Philadelphia | Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors |
US6453244B1 (en) * | 2000-02-10 | 2002-09-17 | Stanford University | Detection of polymorphisms by denaturing high-performance liquid chromatography |
US6492115B1 (en) * | 2000-06-02 | 2002-12-10 | Dna Sciences Laboratories, Inc. | Genetic typing of the human cytochrome P450 2A6 gene and related materials and methods |
HUP0301245A3 (en) | 2000-10-02 | 2005-12-28 | Novo Nordisk Healthcare Ag | Tmethod for the production of vitamin k-dependent proteins |
AU2002226028A1 (en) | 2000-11-14 | 2002-05-27 | Board Of Regents, Unversity Of Texas Systems | Mutant human factor ix with an increased resistance to inhibition by heparin |
ES2453895T3 (en) | 2003-09-23 | 2014-04-08 | University Of North Carolina At Chapel Hill | Cells expressing vitamin K epoxide reductase and use thereof |
EP2272951B1 (en) * | 2003-10-14 | 2014-07-23 | Baxter International Inc. | Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives |
GB0324044D0 (en) * | 2003-10-14 | 2003-11-19 | Astrazeneca Ab | Protein |
CA2583904C (en) | 2004-10-18 | 2018-01-09 | University Of Washington | Methods and compositions for predicting drug responses |
US7445896B2 (en) * | 2004-10-18 | 2008-11-04 | University Of Washington | Methods and compositions for detecting VKORC1 single nucleotide polymorphisms |
KR101178463B1 (en) * | 2004-12-21 | 2012-09-07 | 아카데미아 시니카 | Genetic variants predicting warfarin sensitivity |
US20090100533A1 (en) | 2004-12-21 | 2009-04-16 | Novo Nordisk Health Care Ag | Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host sytems |
AU2006218216B2 (en) * | 2005-02-28 | 2011-01-20 | Baxalta GmbH | Recombinant co-expression of vitamin K epoxide reductase subunit 1 to improve vitamin K dependent protein expression |
AU2005329450A1 (en) | 2005-03-15 | 2006-09-28 | University Of North Carolina At Chapel Hill | Methods and compositions for producing active Vitamin K-dependent proteins |
BRPI0609120A2 (en) | 2005-04-13 | 2010-11-16 | Astrazeneca Ab | cell, vector, and methods for producing gamma carboxylated protein and for producing a pharmaceutical composition |
EP1963506B1 (en) | 2005-12-02 | 2010-10-27 | Wake Forest University Health Sciences | Compositions and methods for increasing production of recombinant gamma-carboxylated proteins |
JP5526332B2 (en) | 2005-12-21 | 2014-06-18 | シーエヌジェイ ホールディングス,インコーポレイテッド | Method for producing bioactive vitamin K-dependent protein by recombinant method |
WO2007143617A1 (en) | 2006-06-02 | 2007-12-13 | Academia Sinica | Warfarin dosage prediction |
JP2009005240A (en) * | 2007-06-25 | 2009-01-08 | Nec Tokin Corp | Radio network system and radio network communication method |
-
2004
- 2004-09-23 ES ES11156979.4T patent/ES2453895T3/en active Active
- 2004-09-23 DE DE602004025157T patent/DE602004025157D1/en active Active
- 2004-09-23 DK DK11156979.4T patent/DK2380985T3/en active
- 2004-09-23 EP EP10178665A patent/EP2336360A1/en not_active Withdrawn
- 2004-09-23 EP EP11156979.4A patent/EP2380985B1/en active Active
- 2004-09-23 AT AT07109353T patent/ATE455174T1/en not_active IP Right Cessation
- 2004-09-23 JP JP2006528251A patent/JP2007506433A/en not_active Withdrawn
- 2004-09-23 EP EP04789039.7A patent/EP1670947B1/en not_active Not-in-force
- 2004-09-23 AU AU2004275828A patent/AU2004275828B2/en active Active
- 2004-09-23 WO PCT/US2004/031481 patent/WO2005030039A2/en active Application Filing
- 2004-09-23 EP EP07109353.8A patent/EP1842920B2/en active Active
- 2004-09-23 ES ES07109353.8T patent/ES2339710T5/en active Active
- 2004-09-23 DK DK07109353.8T patent/DK1842920T4/en active
- 2004-09-23 CA CA2539434A patent/CA2539434C/en active Active
- 2004-09-23 PL PL07109353T patent/PL1842920T5/en unknown
- 2004-09-23 PT PT111569794T patent/PT2380985E/en unknown
- 2004-09-23 US US10/573,131 patent/US7687233B2/en not_active Expired - Fee Related
-
2006
- 2006-09-06 US US11/516,229 patent/US7524665B2/en active Active
- 2006-12-20 HK HK06114003.0A patent/HK1093223A1/en not_active IP Right Cessation
-
2007
- 2007-01-30 US US11/699,930 patent/US7482141B2/en active Active
- 2007-10-26 US US11/924,707 patent/US8097410B2/en not_active Expired - Fee Related
-
2009
- 2009-01-28 US US12/361,053 patent/US7858318B2/en not_active Expired - Fee Related
-
2010
- 2010-07-02 JP JP2010151738A patent/JP5094920B2/en not_active Expired - Fee Related
- 2010-07-26 AU AU2010203318A patent/AU2010203318B2/en not_active Ceased
- 2010-12-17 US US12/971,574 patent/US8426128B2/en not_active Expired - Fee Related
-
2012
- 2012-03-12 JP JP2012054537A patent/JP5840539B2/en active Active
-
2015
- 2015-05-07 JP JP2015094928A patent/JP2015180205A/en active Pending
Non-Patent Citations (1)
Title |
---|
See references of EP1670947A4 * |
Cited By (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7482141B2 (en) | 2003-09-23 | 2009-01-27 | University Of North Carolina At Chapel Hill | Methods and compositions for vitamin K epoxide reductase |
US7524665B2 (en) | 2003-09-23 | 2009-04-28 | University Of North Carolina At Chapel Hill | Methods and compositions for vitamin K epoxide reductase |
US7645602B2 (en) | 2003-09-23 | 2010-01-12 | The University Of North Carolina At Chapel Hill | Methods and compositions for producing vitamin K dependent proteins |
US9441208B2 (en) | 2003-09-23 | 2016-09-13 | The University Of North Carolina At Chapel Hill | Methods and compositions for producing vitamin K dependent proteins |
US7858318B2 (en) | 2003-09-23 | 2010-12-28 | The University Of North Carolina At Chapel Hill | Methods and compositions for vitamin K epoxide reductase |
US7687233B2 (en) | 2003-09-23 | 2010-03-30 | The University Of North Carolina At Chapel Hill | Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage |
US8426128B2 (en) | 2003-09-23 | 2013-04-23 | The University Of North Carolina At Chapel Hill | Methods and compositions for vitamin K epoxide reductase |
US8097410B2 (en) | 2003-09-23 | 2012-01-17 | University Of North Carolina At Chapel Hill | Methods and compositions for vitamin K epoxide reductase |
US7842477B2 (en) | 2003-10-14 | 2010-11-30 | Astrazeneca Ab | Methods for producing gamma-carboxylated proteins |
US20110154520A1 (en) * | 2003-10-14 | 2011-06-23 | Baxter International Inc. | Vitamin K Epoxide Recycling Polypeptide VKORC1, a Therapeutic Target of Coumarin and Their Derivatives |
US7939250B2 (en) * | 2003-10-14 | 2011-05-10 | Baxter International Inc. | Vitamin K epoxide recycling polypeptide VKORC1, a therapeutic target of coumarin and their derivatives |
EP2189523A1 (en) * | 2003-10-14 | 2010-05-26 | Baxter International Inc. | Vitamin K epoxide recycling polypeptide VKORC1, a therapeutic target of coumarin and their derivatives |
US8697440B2 (en) | 2003-10-14 | 2014-04-15 | Medimmune Limited | Compositions and methods for producing gamma-carboxylated proteins |
JP2007512002A (en) * | 2003-10-14 | 2007-05-17 | バクスター・インターナショナル・インコーポレイテッド | Therapeutic targets for vitamin K epoxy recycling polypeptide VKORC1, coumarin and its derivatives |
EP1673450B1 (en) * | 2003-10-14 | 2010-04-28 | Baxter International Inc. | Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives |
JP4777251B2 (en) * | 2003-10-14 | 2011-09-21 | バクスター・インターナショナル・インコーポレイテッド | Therapeutic target of vitamin K epoxide reductase complex subunit 1VKORC1, coumarin and its derivatives |
EP2272951A1 (en) * | 2003-10-14 | 2011-01-12 | Baxter International Inc | Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives |
US7888016B2 (en) | 2004-10-18 | 2011-02-15 | The University Of Washington | Methods and compositions for predicting drug responses |
US9074257B2 (en) | 2004-10-18 | 2015-07-07 | University Of Washington | Methods and compositions for predicting drug responses |
US7445896B2 (en) * | 2004-10-18 | 2008-11-04 | University Of Washington | Methods and compositions for detecting VKORC1 single nucleotide polymorphisms |
US8153366B2 (en) | 2004-10-18 | 2012-04-10 | University Of Washington | Methods and compositions for predicting drug responses |
US8614060B2 (en) | 2004-10-18 | 2013-12-24 | University Of Washington | Methods and compositions for predicting drug responses |
WO2006044686A3 (en) * | 2004-10-18 | 2006-08-03 | Univ Washington | Methods and compositions for predicting drug responses |
US7829282B2 (en) | 2004-10-18 | 2010-11-09 | The University Of Washington | Methods and compositions for predicting drug responses |
JP2008516630A (en) * | 2004-10-18 | 2008-05-22 | ユニヴァーシティ オブ ワシントン | Methods and compositions for predicting drug response |
EP2246445A1 (en) * | 2004-12-21 | 2010-11-03 | Academia Sinica | Genetic variants of VKORC1 predicting warfarin sensitivity |
AU2005319028B2 (en) * | 2004-12-21 | 2010-09-16 | Academia Sinica | Genetic variants of VKORCI predicting warfarin sensitivity |
EP1831402B1 (en) * | 2004-12-21 | 2010-06-09 | Academia Sinica | Genetic variants of vkorc1 predicting warfarin sensitivity |
JP2008531026A (en) * | 2005-02-28 | 2008-08-14 | バクスター・インターナショナル・インコーポレイテッド | Recombinant co-expression of vitamin K epoxide reductase subunit 1 to improve vitamin K-dependent protein expression |
EP2295547B1 (en) | 2005-02-28 | 2017-09-20 | Baxalta GmbH | Recombinant co-expression of vitamin K epoxide reductase subunit 1 to improve vitamin K dependant protein expression |
JP2013063089A (en) * | 2005-02-28 | 2013-04-11 | Baxter Internatl Inc | Recombinant co-expression of vitamin k epoxide reductase subunit 1 to improve vitamin k-dependent protein expression |
JP2008532544A (en) * | 2005-03-15 | 2008-08-21 | ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Methods and compositions for producing active vitamin K-dependent proteins |
EP1861499A4 (en) * | 2005-03-15 | 2008-09-03 | Univ North Carolina | Methods and compositions for producing active vitamin k-dependent proteins |
US8603823B2 (en) | 2005-03-15 | 2013-12-10 | The University Of North Carolina At Chapel Hill | Methods and compositions for producing vitamin K dependent proteins |
EP1861499A1 (en) * | 2005-03-15 | 2007-12-05 | The University of North Carolina at Chapel Hill | Methods and compositions for producing active vitamin k-dependent proteins |
US9828588B2 (en) | 2005-03-15 | 2017-11-28 | The University Of North Carolina At Chapel Hill | Methods and compositions for producing active vitamin K-dependent proteins |
JP2008535517A (en) * | 2005-04-13 | 2008-09-04 | アストラゼネカ アクチボラグ | vector |
US8304224B2 (en) | 2005-04-13 | 2012-11-06 | Medimmune Limited | Compositions and methods relating to proteins requiring gamma-carboxylation |
TWI384070B (en) * | 2005-04-13 | 2013-02-01 | Astrazeneca Ab | Vector |
KR101599062B1 (en) * | 2005-04-13 | 2016-03-02 | 아스트라제네카 아베 | A host cell comprising a vector for production of proteins requiring gamma-carboxylation |
US7989193B2 (en) | 2005-04-13 | 2011-08-02 | Medimmune Limited | Compositions and methods for producing gamma-carboxylated proteins |
AU2006234788B2 (en) * | 2005-04-13 | 2011-07-14 | Medimmune, Limited | A host cell comprising a vector for production of proteins requiring gamma-carboxylation |
KR20080002949A (en) * | 2005-04-13 | 2008-01-04 | 아스트라제네카 아베 | A host cell comprising a vector for production of proteins requiring gamma-carboxylation |
JP2009521224A (en) * | 2005-12-21 | 2009-06-04 | インスピレーション バイオファーマシューティカルズ,インコーポレイテッド | Method for producing bioactive vitamin K-dependent protein by recombinant method |
JP2013223514A (en) * | 2005-12-21 | 2013-10-31 | Inspiration Biopharmaceuticals Inc | Method of producing biologically active vitamin k dependent protein by recombinant method |
AU2006331501B2 (en) * | 2005-12-21 | 2013-09-05 | Aptevo Biotherapeutics Llc | Method of producing biologically active vitamin K dependent proteins by recombinant methods |
JP2017046717A (en) * | 2005-12-21 | 2017-03-09 | シーエヌジェイ ホールディングス,インコーポレイテッド | Method of producing biologically active vitamin k dependent protein by recombinant method |
EP1969127B2 (en) † | 2005-12-21 | 2017-07-12 | Cnj Holdings, Inc | Method of producing biologically active vitamin k dependent proteins by recombinant methods |
WO2007075976A3 (en) * | 2005-12-21 | 2007-10-04 | Inspiration Biopharmaceuticals | Method of producing biologically active vitamin k dependent proteins by recombinant methods |
WO2007075976A2 (en) * | 2005-12-21 | 2007-07-05 | Inspiration Biopharmaceuticals, Inc. | Method of producing biologically active vitamin k dependent proteins by recombinant methods |
US8206967B2 (en) | 2007-07-06 | 2012-06-26 | Medimmune Limited | Method for production of recombinant human thrombin |
WO2009130602A2 (en) | 2008-04-24 | 2009-10-29 | Celtic Pharma Peg Ltd. | Factor ix conjugates with extended half-lives |
US9212214B2 (en) | 2009-07-10 | 2015-12-15 | Csl Limited | Methods of increasing the expression yield of vitamin K-dependent proteins |
US9631002B2 (en) | 2010-12-21 | 2017-04-25 | The University Of North Carolina At Chapel Hill | Methods and compositions for producing active vitamin K-dependent proteins |
JP2012139232A (en) * | 2012-03-15 | 2012-07-26 | Univ Of North Carolina At Chapel Hill | Method and composition for producing active vitamin k-dependent protein |
JP2014221048A (en) * | 2014-06-16 | 2014-11-27 | ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Method and composition for producing active vitamin k-dependent protein |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8426128B2 (en) | Methods and compositions for vitamin K epoxide reductase | |
US20210332333A1 (en) | Methods and compositions for producing active vitamin k-dependent proteins | |
AU2012202110A1 (en) | Methods and compositions for producing active vitamin K-dependent proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004275828 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2539434 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004789039 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2004275828 Country of ref document: AU Date of ref document: 20040923 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006528251 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004275828 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006240440 Country of ref document: US Ref document number: 10573131 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004789039 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10573131 Country of ref document: US |